Vimovo is a brand name of esomeprazole/naproxen, approved by the FDA in the following formulation(s):
VIMOVO (esomeprazole magnesium; naproxen - tablet, delayed release; oral)
Manufacturer: ASTRAZENECA LP
Approval date: April 30, 2010
Strength(s): EQ 20MG BASE;375MG, EQ 20MG BASE;500MG [RLD]
Has a generic version of Vimovo been approved?
No. There is currently no therapeutically equivalent version of Vimovo available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vimovo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Compositions
Patent 5,714,504
Issued: February 3, 1998
Inventor(s): Lindberg; Per Lennart & Von Unge; Sverker
Assignee(s): Astra Aktiebolag
The novel optically pure compounds Na.sup.+, Mg.sup.2+, Li.sup.+, K.sup.+, Ca.sup.2+ and N.sup.+ (R).sub.4 salts of (+)-5-methoxy-2-››(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl!sulfinyl!-1H- benzimidazole or (-)-5-methoxy-2-››(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl!sulfinyl!-1H- benzimidazole, in particular sodium and magnesium salt form thereof, where R is an alkyl with 1-4 carbon atoms, processes for the preparation thereof and pharmaceutical preparations containing the compounds as active ingredients, as well as the use of the compounds in pharmaceutical preparations and intermediates obtained by preparing the compounds.Patent expiration dates:
- February 3, 2015✓✓
- August 3, 2015✓
- February 3, 2015
Omeprazole magnesium salt form
Patent 5,900,424
Issued: May 4, 1999
Inventor(s): Kallstrom; Lars .ANG.ke & Nygren; Monica Annelie
Assignee(s): Astra Aktiebolag
A novel compound form of magnesium omeprazole useful in the manufacture of pharmaceutical formulations, the use of the product and the process for its production are described.Patent expiration dates:
- May 4, 2016✓✓
- November 4, 2016✓
- May 4, 2016
Form of S-omeprazole
Patent 6,369,085
Issued: April 9, 2002
Inventor(s): Hanna; Cotton & Anders; Kronström & Anders; Mattson & Eva; Möller
Assignee(s): AstraZeneca AB
The present invention relates to a novel form of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.Patent expiration dates:
- May 25, 2018✓✓✓
- November 25, 2018✓
- May 25, 2018
Compounds
Patent 6,875,872
Issued: April 5, 2005
Inventor(s): Lindberg; Per Lennart & Von Unge; Sverker
Assignee(s): AstraZeneca
The novel optically pure compounds Na+, Mg2+, Li+, K+, Ca2+ and N+(R)4 salts of (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole or (−)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, in particular sodium and magnesium salt form thereof, where R is an alkyl with 1-4 carbon atoms, processes for the preparation thereof and pharmaceutical preparations containing the compounds as active ingredients, as well as the use of the compounds in pharmaceutical preparations and intermediates obtained by preparing the compounds.Patent expiration dates:
- May 27, 2014✓
- November 27, 2014✓
- May 27, 2014
Pharmaceutical compositions for the coordinated delivery of NSAIDs
Patent 6,926,907
Issued: August 9, 2005
Inventor(s): Plachetka; John R.
Assignee(s): Pozen Inc.
The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.Patent expiration dates:
- February 28, 2023✓✓
- February 28, 2023
Form of S-omeprazole
Patent 7,411,070
Issued: August 12, 2008
Inventor(s): Cotton; Hanna & Kronström; Anders & Mattson; Anders & Möller; Eva
Assignee(s): AstraZeneca AB
The present invention relates to a novel form of the (−)-enantiomer of 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.Patent expiration dates:
- May 25, 2018✓✓
- November 25, 2018✓
- May 25, 2018
Form of S-omeprazole
Patent 7,745,466
Issued: June 29, 2010
Inventor(s): Cotton; Hanna & Kronström; Anders & Mattson; Anders & Möller; Eva
Assignee(s): AstraZeneca AB
The present invention relates to a novel form of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.Patent expiration dates:
- October 13, 2018✓✓
- October 13, 2018
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- April 30, 2013 - NEW COMBINATION
See also...
- Vimovo Consumer Information (Drugs.com)
- Vimovo Delayed-Release Tablets Consumer Information (Wolters Kluwer)
- Vimovo Consumer Information (Cerner Multum)
- Vimovo Advanced Consumer Information (Micromedex)
- Naproxen/Esomeprazole Delayed-Release Tablets Consumer Information (Wolters Kluwer)
- Esomeprazole and naproxen Consumer Information (Cerner Multum)
- Naproxen and esomeprazole Advanced Consumer Information (Micromedex)
No comments:
Post a Comment